Alternative targets under consideration for NMO therapy include the AQP4-IgG antibody and its binding to AQP4 [40], complement and complement inhibitory proteins [32, 33] and various immune cells including plasma cells and granulocytes [7, 11, 16, 28]. The gene discussed is AQP4; the disease is neuromyelitis optica.